Trial Profile

A Single Center, Two-part, Double-blind, Randomized, Placebo-controlled, Dose-escalation, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BB-025 or Placebo, Alone and Following a Single Dose of BB-031, in Healthy Volunteers

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BB 025 (Primary) ; BB 031 (Primary)
Indications Blood coagulation disorders; Ischaemic stroke; Pulmonary embolism
Focus Adverse reactions; First in man
Sponsors Basking Biosciences

12 Nov 2025 According to Basking Biosciences media release, the first participants have been dosed in this trial.
22 Oct 2025 According to Basking Biosciences media release, the company unlocks $27.5 Million financing tranche, The new funds will support the execution of planned Phase 1 study of BB-025
08 Oct 2025 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com